PPARG and breast cancer: These findings also show that combination anticancer therapy does not always result in an additive or synergistic anticancer response, but can result in a paradoxical/antagonistic response as was observed with the combined treatment of γ-tocotrienol with PPARγ agonist in MCF-7 and MDA-MB-231 human breast cancer cells.